Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS (NASDAQ:ALXO)

Searching for Alpha’s Disclaimer: This text was routinely generated by an AI instrument based mostly on content material obtainable on the Searching for Alpha web site, and has not been curated or reviewed by people. Because of inherent limitations in utilizing AI-based instruments, the accuracy, completeness, or timeliness of such articles can’t be assured. This text is meant for informational functions solely. Searching for Alpha doesn’t take account of your targets or your monetary scenario and doesn’t supply any customized funding recommendation. Searching for Alpha isn’t a licensed securities vendor, dealer or US funding adviser or funding financial institution.